| Name | Title | Contact Details |
|---|
SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum PCV compared head-to-head to current vaccines using well accepted immunological endpoints. In addition to its lead PCV product candidate, the Company also has a promising early-stage pipeline addressing other important disease areas. SutroVax`s conjugate vaccines are developed utilizing the Company`s exclusive rights to Sutro Biopharma`s Xpress CF Platform, a cell-free protein synthesis technology. SutroVax closed its $85M Series C round in May of 2018 and is financed by a world-class syndicate of private equity, venture capital and corporate venture investors with over $170M in capital raised since 2015.
Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.
SciMed Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Knopp Neurosciences is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.